Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial.

Clinical decision support implemented with academic detailing improves prescribing of key renally cleared drugs in the hospital setting. J Am Med Inform Assoc (2010) 0.94

Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study. J Interv Cardiol (2014) 0.94

Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Arch Med Sci (2013) 0.92

Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: the FERARI study. Heart Vessels (2016) 0.79

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept? Curr Cardiol Rev (2008) 0.77

Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. Heart Vessels (2010) 0.75

The future of an illusion. J Am Coll Cardiol (2006) 0.75

Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. Am Heart J (2016) 0.75

Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics. Clin Res Cardiol (2010) 0.75

Interaction between access choice and pharmacotherapy for coronary intervention: the results of a UK survey. Open Heart (2014) 0.75

Variability of antithrombotic dosing among veterans presenting with acute coronary syndrome. J Am Heart Assoc (2015) 0.75

New scoring model (DARSYM score) to predict post-discharge bleeding after successful second-generation drug-eluting stent implantation. Heart Vessels (2017) 0.75

Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med (2010) 22.04

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57

Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95

Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med (1985) 7.29

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (2009) 6.19

Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA (2010) 6.11

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20

Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19

Non-evidence-based ICD implantations in the United States. JAMA (2011) 5.05

Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99

Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation (2011) 4.95

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet (2008) 4.71

Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol (2008) 4.51

ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation (2004) 4.49

Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48

Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med (2012) 4.47

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31

Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med (2015) 4.27

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16

Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10

Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09

Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00

The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78

Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg (2006) 3.77

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA (2012) 3.71

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 3.55

Race and gender differences in C-reactive protein levels. J Am Coll Cardiol (2005) 3.51

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45

The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation (2003) 3.45

Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA (2011) 3.44

Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. Circulation (2005) 3.38

Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation (2006) 3.35

Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31

Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol (2012) 3.29

Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J (2005) 3.26

Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol (2009) 3.26

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation (2008) 3.25

Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol (2005) 3.20

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17

Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation (2005) 3.16

Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA (2008) 3.12

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07

Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol (2012) 3.01

Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA (2010) 2.98

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA (2005) 2.93

Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J (2008) 2.92

Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation (2002) 2.86

B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation (2002) 2.85

Prevalence and determinants of troponin T elevation in the general population. Circulation (2006) 2.84

Comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the Assessing Angiography (A2) project. Circulation (2013) 2.81

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2010) 2.76

Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2012) 2.76

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2008) 2.75

Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA (2002) 2.75

Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72

Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation (2012) 2.71

Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation (2003) 2.70

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2007) 2.64

Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62